TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Patent ExpiryapprovedDelta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC)Positive

AI Analysis

Summary

TuHURA Biosciences received a U.S. patent for its delta opioid receptor antibody drug conjugate technology, with disclosed uses extending to adoptive cellular immunotherapies including CAR-T, Tregs, and TIL cell therapies.

Outcome Details

U.S. patent granted for DOR antibody drug conjugate technology and applications including CAR-T, Tregs, and TIL cell therapies

Importance:5/10

Sentiment:

0.60

patentDOR antibodyADCCAR-Timmuno-oncologycellular immunotherapy

Related Companies

$HURA

Read the original article

Published by PR Newswire Biotech on October 5, 2026 11:45 AM

Read Original